Alembic Pharmaceuticals Share Price
Sector: Biotechnology & Drugs
970.00 -58.25 (-5.66%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
962.00
Today’s High
1018.00
52 Week Low
725.60
52 Week High
1296.15
968.00 -60.65 (-5.90%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
961.55
Today’s High
1019.95
52 Week Low
725.20
52 Week High
1303.90
Key Metrics
- Market Cap (In Cr) 19066.62
- Beta 0.72
- Div. Yield (%) 1.07
- P/B 3.9
- TTM P/E 31.39
- Peg Ratio 9.03
- Sector P/E 24.5
- D/E 0
- Open Price 1018
- Prev Close 1028.25
Alembic Pharmaceuticals Analysis
Price Analysis
-
1 Week16.95%
-
3 Months26.17%
-
6 Month0.39%
-
YTD-3.53%
-
1 Year6.29%
Risk Meter
- 39% Low risk
- 39% Moderate risk
- 39% Balanced Risk
- 39% High risk
- 39% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 3
- 2
- 3
- Buy
- 2
- 2
- 1
- 1
- Hold
- 5
- 5
- 5
- 5
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 1
- 1
- 1
- 1
- Total
- 11
- 11
- 9
- 10
Alembic Pharmaceuticals News
Alembic Pharma Q3 Results: Net profit declines 23% to ₹138 cr, stock down 5%
1 min read . 03 Feb 2025Alembic Pharmaceuticals Q2 Results Live: Profit Rise by 12.33% YOY
1 min read . 08 Nov 2024Stocks to Watch: Tech Mahindra, HDFC Bank, Kotak Bank, Jio Financial, and more
3 min read . 21 Oct 2024Mahindra, Max Life Insurance, Alembic Pharma take lead in PM internship scheme
2 min read . 03 Oct 2024Alembic Pharmaceuticals Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 6672.08
- Selling/ General/ Admin Expenses Total
- 1562.34
- Depreciation/ Amortization
- 278.58
- Other Operating Expenses Total
- 2308.15
- Total Operating Expense
- 5929.56
- Operating Income
- 742.52
- Net Income Before Taxes
- 707.18
- Net Income
- 583.42
- Diluted Normalized EPS
- 29.14
- Period
- 2025
- Total Assets
- 7772.94
- Total Liabilities
- 2582
- Total Equity
- 5190.94
- Tangible Book Valueper Share Common Eq
- 264.09
- Period
- 2025
- Cashfrom Operating Activities
- 87.97
- Cashfrom Investing Activities
- -568.41
- Cashfrom Financing Activities
- 443.71
- Net Changein Cash
- -36.73
- Period
- 2024
- Total Revenue
- 6228.63
- Selling/ General/ Admin Expenses Total
- 2715.31
- Depreciation/ Amortization
- 272.67
- Other Operating Expenses Total
- 21.4
- Total Operating Expense
- 5567.9
- Operating Income
- 660.73
- Net Income Before Taxes
- 631.83
- Net Income
- 615.83
- Diluted Normalized EPS
- 31.25
- Period
- 2024
- Total Assets
- 6445.58
- Total Liabilities
- 1627.38
- Total Equity
- 4818.2
- Tangible Book Valueper Share Common Eq
- 245.12
- Period
- 2024
- Cashfrom Operating Activities
- 803.21
- Cashfrom Investing Activities
- -320.61
- Cashfrom Financing Activities
- -437.87
- Net Changein Cash
- 44.73
- Period
- 2023
- Total Revenue
- 5652.62
- Selling/ General/ Admin Expenses Total
- 2178.21
- Depreciation/ Amortization
- 275.43
- Other Operating Expenses Total
- 17.57
- Total Operating Expense
- 5214.84
- Operating Income
- 437.78
- Net Income Before Taxes
- 354.59
- Net Income
- 341.98
- Diluted Normalized EPS
- 17.63
- Period
- 2023
- Total Assets
- 6182.83
- Total Liabilities
- 1812.36
- Total Equity
- 4370.47
- Tangible Book Valueper Share Common Eq
- 222.34
- Period
- 2023
- Cashfrom Operating Activities
- 723.96
- Cashfrom Investing Activities
- -447.59
- Cashfrom Financing Activities
- -261.96
- Net Changein Cash
- 14.4
- Period
- 2022
- Total Revenue
- 5305.79
- Selling/ General/ Admin Expenses Total
- 1945.86
- Depreciation/ Amortization
- 286.78
- Other Operating Expenses Total
- 12.67
- Total Operating Expense
- 4718.33
- Operating Income
- 587.46
- Net Income Before Taxes
- 620.11
- Net Income
- 520.93
- Diluted Normalized EPS
- 26.48
- Period
- 2022
- Total Assets
- 7122.03
- Total Liabilities
- 1884.48
- Total Equity
- 5237.55
- Tangible Book Valueper Share Common Eq
- 258.58
- Period
- 2022
- Cashfrom Operating Activities
- 552.35
- Cashfrom Investing Activities
- -371.97
- Cashfrom Financing Activities
- -217.35
- Net Changein Cash
- -36.97
- Period
- 2021
- Total Revenue
- 5393.13
- Selling/ General/ Admin Expenses Total
- 1745.86
- Depreciation/ Amortization
- 183.47
- Other Operating Expenses Total
- 8.41
- Total Operating Expense
- 4096.3
- Operating Income
- 1296.83
- Net Income Before Taxes
- 1368.08
- Net Income
- 1146.5
- Diluted Normalized EPS
- 59.12
- Period
- 2021
- Total Assets
- 6708.98
- Total Liabilities
- 1642.01
- Total Equity
- 5066.97
- Tangible Book Valueper Share Common Eq
- 241.31
- Period
- 2021
- Cashfrom Operating Activities
- 1463.38
- Cashfrom Investing Activities
- -838.81
- Cashfrom Financing Activities
- -597.43
- Net Changein Cash
- 26.21
- Period
- 2020
- Total Revenue
- 4605.75
- Selling/ General/ Admin Expenses Total
- 1432.08
- Depreciation/ Amortization
- 157.32
- Other Operating Expenses Total
- 27.44
- Total Operating Expense
- 3592.13
- Operating Income
- 1013.62
- Net Income Before Taxes
- 999.82
- Net Income
- 828.81
- Diluted Normalized EPS
- 48.07
- Period
- 2020
- Total Assets
- 5989.05
- Total Liabilities
- 2769.64
- Total Equity
- 3219.41
- Tangible Book Valueper Share Common Eq
- 154.91
- Period
- 2020
- Cashfrom Operating Activities
- 449.13
- Cashfrom Investing Activities
- -731.63
- Cashfrom Financing Activities
- 154.85
- Net Changein Cash
- -127.24
- Period
- 2025-03-31
- Total Revenue
- 1769.64
- Selling/ General/ Admin Expenses Total
- 393.59
- Depreciation/ Amortization
- 68.99
- Other Operating Expenses Total
- 573.51
- Total Operating Expense
- 1566.7
- Operating Income
- 202.94
- Net Income Before Taxes
- 191.95
- Net Income
- 156.9
- Diluted Normalized EPS
- 7.98
- Period
- 2025-03-31
- Total Assets
- 7772.94
- Total Liabilities
- 2582
- Total Equity
- 5190.94
- Tangible Book Valueper Share Common Eq
- 264.09
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 87.97
- Cashfrom Investing Activities
- -568.41
- Cashfrom Financing Activities
- 443.71
- Net Changein Cash
- -36.73
- Period
- 2024-12-31
- Total Revenue
- 1692.74
- Selling/ General/ Admin Expenses Total
- 397.52
- Depreciation/ Amortization
- 70.04
- Other Operating Expenses Total
- 595.45
- Total Operating Expense
- 1502.55
- Operating Income
- 190.19
- Net Income Before Taxes
- 177.78
- Net Income
- 138.42
- Diluted Normalized EPS
- 7.01
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1647.98
- Selling/ General/ Admin Expenses Total
- 391.47
- Depreciation/ Amortization
- 70.51
- Other Operating Expenses Total
- 588.13
- Total Operating Expense
- 1466.36
- Operating Income
- 181.62
- Net Income Before Taxes
- 180.42
- Net Income
- 153.4
- Diluted Normalized EPS
- 7.24
- Period
- 2024-09-30
- Total Assets
- 7230.25
- Total Liabilities
- 2342.19
- Total Equity
- 4888.06
- Tangible Book Valueper Share Common Eq
- 248.68
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -100.97
- Cashfrom Investing Activities
- -193.57
- Cashfrom Financing Activities
- 296.38
- Net Changein Cash
- 1.84
- Period
- 2024-06-30
- Total Revenue
- 1561.73
- Selling/ General/ Admin Expenses Total
- 379.77
- Depreciation/ Amortization
- 69.04
- Other Operating Expenses Total
- 551.04
- Total Operating Expense
- 1393.94
- Operating Income
- 167.79
- Net Income Before Taxes
- 157.03
- Net Income
- 134.37
- Diluted Normalized EPS
- 6.84
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1516.98
- Selling/ General/ Admin Expenses Total
- 401.84
- Depreciation/ Amortization
- 69.48
- Other Operating Expenses Total
- 475.72
- Total Operating Expense
- 1326.4
- Operating Income
- 190.58
- Net Income Before Taxes
- 182.85
- Net Income
- 178.21
- Diluted Normalized EPS
- 9.07
- Period
- 2024-03-31
- Total Assets
- 6445.58
- Total Liabilities
- 1627.38
- Total Equity
- 4818.2
- Tangible Book Valueper Share Common Eq
- 245.12
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 803.21
- Cashfrom Investing Activities
- -320.61
- Cashfrom Financing Activities
- -437.87
- Net Changein Cash
- 44.73
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Alembic Pharmaceuticals Technical
Moving Average
SMA
- 5 Day901.87
- 10 Day900.06
- 20 Day885.04
- 50 Day865.6
- 100 Day909.54
- 300 Day1018.95
Alembic Pharmaceuticals Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Gland Pharma
- 1498.5
- 14.35
- 0.97
- 2220.95
- 1200
- 24688.75
- Wockhardt
- 1325
- -34.35
- -2.53
- 1678.6
- 489.2
- 21535.59
- Alembic Pharmaceuticals
- 970
- -58.25
- -5.66
- 1296.15
- 725.6
- 19066.62
- Eris Lifesciences
- 1463.05
- 19.6
- 1.36
- 1593
- 815.5
- 20043.28
- Caplin Point Laboratories
- 2141
- -21.55
- -1
- 2636
- 1221
- 16274.1
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Gland Pharma
- 31.65
- 2.8
- 14.89
- 22.92
- Wockhardt
- -
- 6.21
- -10.63
- -12.7
- Alembic Pharmaceuticals
- 35.3
- 3.9
- 13.54
- 10.84
- Eris Lifesciences
- 55.94
- 6.89
- 18.25
- 20.85
- Caplin Point Laboratories
- 30.76
- 5.76
- 21.81
- 26.11
Alembic Pharmaceuticals Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 06-May-25
- Audited Results & Final Dividend
- 03-Feb-25
- Quarterly Results & Others
- 07-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 09-May-24
- Audited Results & Final Dividend
- 05-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 04-Aug-23
- Quarterly Results
- 05-May-23
- Audited Results & Final Dividend
- 01-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 18-Mar-25
- 12-Feb-25
- POM
- 22-Jul-24
- 21-Jun-24
- AGM
- 04-Aug-23
- 05-May-23
- AGM
- 30-Sept-22
- 02-May-22
- AGM
- 14-Jun-22
- 10-May-22
- COM
- 19-Mar-22
- 11-Feb-22
- POM
- 27-Jul-21
- 15-Jun-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 06-May-25
- -
- -
- 11
- 09-May-24
- 15-Jul-24
- 15-Jul-24
- 11
- 05-May-23
- 28-Jul-23
- 28-Jul-23
- 8
- 02-May-22
- 18-Aug-22
- 17-Aug-22
- 10
- 04-May-21
- -
- 19-Jul-21
- 14


